TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Egetis Therapeutics AB (publ)
Closing information (x1000 EUR)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover |
5,191
|
2,031
|
3,739 |
Financial expenses |
622
|
63
|
18 |
Earnings before taxes |
-29,452
|
-17,415
|
-10,222 |
EBITDA |
-28,947
|
-17,559
|
-10,094 |
Total assets |
68,511
|
50,421
|
55,664 |
Current assets |
31,173
|
13,246
|
14,951 |
Current liabilities |
9,364
|
4,439
|
3,830 |
Equity capital |
49,171
|
45,488
|
51,535 |
- share capital |
1,388
|
1,015
|
850 |
Employees (average) |
27
|
15
|
11 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency |
71.8%
|
90.2%
|
92.6% |
Turnover per employee |
192
|
135
|
340 |
Profit as a percentage of turnover |
-567.4%
|
-857.5%
|
-273.4% |
Return on assets (ROA) |
-42.1%
|
-34.4%
|
-18.3% |
Current ratio |
332.9%
|
298.4%
|
390.4% |
Return on equity (ROE) |
-59.9%
|
-38.3%
|
-19.8% |
Change turnover |
3,154
|
-1,406
|
-237 |
Change turnover % |
155%
|
-41%
|
-6% |
Chg. No. of employees |
12
|
4
|
2 |
Chg. No. of employees % |
80%
|
36%
|
22% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.